RxDoctor Payments Data

Clark Roberts, APRN

Family · Little Rock, ARNPI 1710448535

Payments from drug & device makers

$802in general payments, 2019–2025

Across 23 payments — averaging $34.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$192
  • Gilead$191
  • AstraZeneca$96
  • Vanda Pharmaceuticals Inc.$57
  • Viiv Healthcare Company$55
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$52
  • plus $159 from 6 others

What the payments were for

  • Food & beverage$802100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$802 in reported general payments places this provider in the 65th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$443
Medicare patients
14
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$38,114
FarxigaDapagliflozin Propanediol36$22,015
JanuviaSitagliptin Phosphate28$18,659
EliquisApixaban23$15,005
JanumetSitagliptin Phos/Metformin Hcl18$14,445
EntrestoSacubitril/Valsartan13$10,775
Albuterol Sulfate HfaAlbuterol Sulfate78$2,636
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,890
Comfort Ez Pen NeedlePen Needle, Diabetic15$1,338
Atorvastatin Calcium217$1,046
Omeprazole86$1,038
Amlodipine Besylate224$962
Fluticasone Propionate50$918
Gabapentin66$787
Losartan Potassium132$734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$192$38,11433 claims
AstraZenecaFarxiga$96$22,01536 claims
PfizerEliquis$15$15,00523 claims
NovartisEntresto$29$10,77513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,103 family providers in Arkansas.

Other family in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →